How to Help Your Patients Save Money on Vemlidy: A Provider's Guide to Savings Programs

Medication adherence is the cornerstone of successful chronic hepatitis B management — and cost is one of the most common reasons patients don't fill or continue their prescriptions. For Vemlidy (tenofovir alafenamide, TAF), the financial barrier is significant: the cash price ranges from $1,500 to $1,800 per month, and with no generic currently marketed in the United States, many patients face substantial out-of-pocket costs even with insurance.

As a provider, you're in a unique position to help. By understanding the savings programs available and incorporating cost discussions into your clinical workflow, you can improve adherence and outcomes for your hepatitis B patients. This guide covers the practical tools and programs at your disposal.

Understanding the Financial Landscape for Vemlidy

Before counseling patients, it helps to understand the financial terrain they're navigating:

Commercially insured patients: Copays vary widely. Some plans cover Vemlidy with a specialty tier copay of $50–$200+/month. Others require prior authorization or step therapy through TDF first.

Medicare Part D patients: Most plans cover Vemlidy (typically Tier 5). Since 2025, the $2,000 annual Part D OOP cap under the Inflation Reduction Act limits maximum patient exposure. However, cost before reaching the cap can still be substantial. Manufacturer co-pay programs are NOT available for Medicare patients.

Uninsured patients: Without assistance, the full cash price makes Vemlidy unaffordable for most. Patient assistance programs are the primary resource.

Generic availability: As of early 2026, no generic tenofovir alafenamide is marketed in the US. FDA has approved generic manufacturing, but products are not yet commercially available.

Program 1: Gilead Support Path Co-Pay Coupon Program

For commercially insured patients, the Gilead Support Path Co-Pay program is the most impactful cost-reduction tool available.

Benefit: Covers patient out-of-pocket costs (copay, coinsurance, deductible amounts) up to $6,000 per year, with no monthly limit

Outcome: Since 2018, over 90% of commercially insured enrolled patients have paid $0 per prescription

Eligibility: Commercially insured patients only. NOT available to Medicare, Medicaid, TRICARE, or VA patients.

Enrollment: Patients register at vemlidy.com/savings or call 1-855-769-7284 (M–F, 9 AM–8 PM ET). Multilingual support available in Chinese, Korean, and Vietnamese — critical given that hepatitis B disproportionately affects Asian and Pacific Islander communities.

Practice workflow tip: Your medical assistant or care coordinator can assist patients with enrollment during the visit. Many specialty pharmacies will also enroll patients at the time of dispense. Having a printed handout or QR code linking to the enrollment page can help patients who need to complete it at home.

Program 2: Gilead Advancing Access Patient Assistance Program (PAP)

For patients who are uninsured or whose insurance doesn't cover Vemlidy, Gilead's Advancing Access program provides medication at no cost to qualifying individuals.

Benefit: Free Vemlidy for eligible patients. This is particularly important for the HBV patient population, which includes many uninsured immigrants and individuals with limited incomes.

Eligibility: Uninsured or underinsured US residents meeting income criteria. Your provider's statement of medical necessity is typically required.

Contact: gileadadvancingaccess.com or 1-800-226-2056

Practice workflow tip: Build PAP applications into your social work or case management workflow. Identify patients who are uninsured or underinsured at scheduling and flag them for financial counseling before or during the initial consultation. Your staff can complete much of the application paperwork on the patient's behalf.

Program 3: 340B Drug Pricing at Qualifying Facilities

If your practice or hospital participates in the federal 340B Drug Pricing Program, you can access Vemlidy at significantly reduced prices for qualifying patients (those receiving care at a covered entity). 340B pricing is typically available at:

Federally qualified health centers (FQHCs)

Ryan White HIV/AIDS Program grantees (if patient has HBV/HIV coinfection)

Children's hospitals and certain critical access hospitals

Safety net hospitals and disproportionate share hospitals (DSHs)

Strategies for Medicare Patients

Medicare patients are ineligible for Gilead's commercial co-pay program. However, several approaches can reduce their cost burden:

IRA out-of-pocket cap: Under the Inflation Reduction Act (2025), Medicare Part D annual OOP is capped at $2,000. While patients may still have significant early-year costs, their annual exposure is capped.

Extra Help (Low Income Subsidy): Eligible low-income Medicare patients may qualify for Extra Help, dramatically reducing Part D costs. Screen patients for eligibility at each visit.

Plan optimization: During Medicare open enrollment (October 15–December 7), encourage patients to compare Part D plans using Medicare's plan finder tool to select the plan with the lowest Vemlidy cost-sharing.

Incorporating Cost Conversations Into Your Clinical Workflow

Brief, specific cost conversations at the point of prescribing significantly improve adherence. Being able to say "Vemlidy costs about $1,500 a month without insurance, but there's a program that can bring that down to $0 for many patients" is far more useful than vague reassurance.

Delegate enrollment paperwork to medical assistants, nurse coordinators, social workers, or pharmacy staff — don't let it fall entirely on the prescriber

Check at follow-up visits whether patients actually filled and are taking their Vemlidy — non-adherence due to cost is common and often unreported

Create a simple one-page handout listing the co-pay program, PAP, and medfinder with QR codes or phone numbers for each

When Patients Can't Find Vemlidy in Stock

Cost and access are often intertwined — a patient who finds Vemlidy available only at a higher-cost out-of-network pharmacy may abandon the prescription entirely. When patients report fill problems, direct them to medfinder for Providers, which can locate pharmacies in their area with confirmed Vemlidy stock. Combined with co-pay assistance, this addresses both the access and cost dimensions simultaneously.

For a step-by-step workflow on helping patients find Vemlidy in stock, see: How to Help Your Patients Find Vemlidy in Stock: A Provider's Guide.